Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016

  • ID: 3804697
  • Company Profile
  • 59 pages
  • Global Markets Direct
1 of 4
Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

‘Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ligand Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ligand Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Ligand Pharmaceuticals, Inc.
- The report provides overview of Ligand Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ligand Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ligand Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Ligand Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ligand Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ligand Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Ligand Pharmaceuticals, Inc. Snapshot

Ligand Pharmaceuticals, Inc. Overview

Key Information

Key Facts

Ligand Pharmaceuticals, Inc. - Research and Development Overview

Key Therapeutic Areas

Ligand Pharmaceuticals, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Ligand Pharmaceuticals, Inc. - Pipeline Products Glance

Ligand Pharmaceuticals, Inc. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Ligand Pharmaceuticals, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Ligand Pharmaceuticals, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Ligand Pharmaceuticals, Inc. - Drug Profiles

lasofoxifene tartrate

Product Description

Mechanism of Action

R&D Progress

clopidogrel bisulfate

Product Description

Mechanism of Action

R&D Progress

aplindore fumarate

Product Description

Mechanism of Action

R&D Progress

pradefovir mesylate

Product Description

Mechanism of Action

R&D Progress

MB-07133

Product Description

Mechanism of Action

R&D Progress

LGD-6972

Product Description

Mechanism of Action

R&D Progress

Drug to Inhibit JAK3 for Inflammation

Product Description

Mechanism of Action

R&D Progress

LG-7455

Product Description

Mechanism of Action

R&D Progress

LGD-3437

Product Description

Mechanism of Action

R&D Progress

LGD-7501

Product Description

Mechanism of Action

R&D Progress

PS-031291

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize CCR1 for Oncology

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes

Product Description

Mechanism of Action

R&D Progress

Ligand Pharmaceuticals, Inc. - Pipeline Analysis

Ligand Pharmaceuticals, Inc. - Pipeline Products by Target

Ligand Pharmaceuticals, Inc. - Pipeline Products by Route of Administration

Ligand Pharmaceuticals, Inc. - Pipeline Products by Molecule Type

Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action

Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates

Ligand Pharmaceuticals, Inc. - Dormant Projects

Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

adipiplon

clopidogrel bisulfate

LGD-5552

managlinat dialanetil

NGD-2000-1

NGD-91-1

NGD-91-2

NGD-91-3

NGD-94-1

NGD-94-4

NGD-96-1

NGD-97-1

Vanilloid Receptor-1 Program

Ligand Pharmaceuticals, Inc. - Company Statement

Ligand Pharmaceuticals, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 59List of Tables

Ligand Pharmaceuticals, Inc., Key Information

Ligand Pharmaceuticals, Inc., Key Facts

Ligand Pharmaceuticals, Inc. - Pipeline by Indication, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016

Ligand Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016

Ligand Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Ligand Pharmaceuticals, Inc. - Pre-Registration, 2016

Ligand Pharmaceuticals, Inc. - Phase III, 2016

Ligand Pharmaceuticals, Inc. - Phase II, 2016

Ligand Pharmaceuticals, Inc. - Phase I, 2016

Ligand Pharmaceuticals, Inc. - Preclinical, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Target, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016

Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016

Ligand Pharmaceuticals, Inc. - Dormant Developmental Projects,2016

Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016

Ligand Pharmaceuticals, Inc., Subsidiaries 56List of Figures

Ligand Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016

Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Ligand Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll